Mark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.
Mark R. Middleton, MD, PhD
Advertisement
Articles by Mark R. Middleton, MD, PhD
Advertisement
Latest Updated Articles
A Bispecific Immunotherapy for the Treatment of MelanomaApril 23rd 2015
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
3
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5